FTH

FTH is a pre-revenue clinical-stage biotech that has, in essence, just become a different company. The MD&A discloses a 1-for-20 reverse stock split effective June 16, 2025, a 65% reduction in force in November 2025 (the '2025 Restructuring'), and a February 17, 2026 acquisition of Faeth Therapeutics that brought in the new lead asset PIKTOR and $200M in gross private-placement proceeds. The reported balance sheet — $22.9M total assets, $8.67M cash, $18.6M equity, 1.34M shares outstanding — reflects only the pre-acquisition shell and is essentially obsolete; the real story is the post-deal capital structure, which is not in the numbers provided.

The fundamentals that ARE reported are uniformly poor: zero product revenue across FY2021–FY2025, cumulative net losses producing a -$283M accumulated deficit, ROE of -113.4%, and FY2025 operating cash burn of -$20.5M. Even the 'improvement' to a -$21.1M net loss is explicitly attributed in MD&A to winding down legacy programs (solnerstotug/SNS-101) and the two restructurings — not to commercial progress. Management openly states R&D and G&A 'will increase significantly' as PIKTOR advances, so the burn rate is set to re-accelerate.